期刊文献+

肝能滴丸治疗慢性乙型肝炎的临床研究 被引量:12

Clinical Study on Effect of Ganneng Dripping Pill in Treating Chronic Hepatitis B
在线阅读 下载PDF
导出
摘要 目的观察中药肝能滴丸治疗慢性乙型肝炎患者临床抗病毒疗效。方法选取乙肝病毒主要复制指标HBV-DNA、HBsAg、HBeAg阳性慢性乙型肝炎患者共84例,开放随机分为肝能滴丸治疗组56例和拉米夫定对照组28例,疗程0·5年;观察两组患者血清HBeAg、HBV-DNA的阴转率和肝功能、症状、体征变化情况。结果治疗组HBV-DNA阴转率为54·0%(27/50例)、HBeAg阴转率30·0%(15/50例)、ALT复常率80·0%(40/50例);对照组依次为67·9%(19/28例)、21·4%(6/28例)、75·0%(21/28例);两组比较差异均无显著性(均P>0·05)。治疗组AST复常率98·0%(48/49例),对照组为48·0%(12/25例),两组比较差异有显著性(P<0·01)。治疗组症状改善以胁肋胀痛、纳食减少、倦怠乏力、脘闷腹胀、尿黄最为显著,明显优于治疗前(P<0·05或P<0·01)。结论肝能滴丸对慢性乙型肝炎有较好的近期疗效;能有效抑制HBV复制,改善肝功能及症状体征。 Objective To observe the antiviral efficacy of Ganneng Dripping Pill (GDP) in treating patients with chronic hepatitis B. Methods Eighty-four patients of chronic hepatitis B with positive HBV-DNA, HBsAg, and HBeAg were randomly assigned to 2 groups, the treated group (56 patients) treated with GDP and the control group (28 patients) treated with lamivudine. The therapeutic course for both groups was 6 months. The negative conversion rate of HBeAg and HBV-DNA, changes of liver function, symptoms and physical signs in patients were observed before and after treatment. Results In the treated group, the negative conversion rate of HBV-DNA and HBeAg was 54.0% (27/50) and 30.0% (15/50) respectively, and the ALT normalizing rate was 80.0% (40/50), while those were 67.86% (19/28), 21.8% (6/28) and 75.0% (21/28) respectively in the control group, showing no significant difference between the two groups (all P 〉0.05). However, the AST normalizing rate was 97.96% (48/49) in the treated group, higher than that in the control group (48.0 %, 12/25, P 〈 0.01) ; and the clinical symptoms, especially the poor appetite, lassitude, gastric distention and yellow urine, were improved more significantly in the treated group than those in the control group (P 〈 0.05 or P 〈 0.01). Conclusion GDP has a favorable short-term effect on chronic hepatitis B, it could effectively inhibit HBV replication and improve the liver function, symptoms and signs in patients.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2006年第9期788-790,共3页 Chinese Journal of Integrated Traditional and Western Medicine
基金 北京市重大创新基金资助项目(No.D0204003040931)
关键词 慢性乙型肝炎 肝能滴丸 拉米夫定 抗病毒 chronic hepatitis B Ganneng Dripping Pill lamivudine anti-viral therapy
  • 相关文献

参考文献6

二级参考文献6

  • 1袁海龙.波棱素化合物及其制法和其药物组合物与用途[P].国家发明专利,申请号:03123965X..
  • 2陈鸿珊 李壮 钱荷英.阿糖腺苷单磷酸鸭乙型肝炎的治疗[J].中华实验和临床病毒学杂志,1983,1:64-64.
  • 3Tsiquaye KN.Maternal trans mission of duck hepatitis B virus in Peajgree Pekin ducks[J].HePatology,1985,5:622.
  • 4陈渊清 顾建人 蒋惠秋.阿糖腺苷单磷酸鸭乙型肝炎的治疗效果[J].中华传染病杂志,1983,1:64-64.
  • 5杨永刚 李壮 陈鸿珊.鸭乙型肝炎病毒感染后在外周和肝脏中的动态[J].病毒学报,1988,4:259-259.
  • 6杨铁虹,卢保华,贾敏,梅其炳.当归多糖对小鼠免疫功能的影响[J].中国药理学通报,2003,19(4):448-451. 被引量:92

共引文献14044

同被引文献168

引证文献12

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部